Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA

Adherence to TNFi follows different trajectories Cluster 1: “moderate then high” 51% Cluster 2: “moderate then low” 20% Cluster 3: “low adherence, to discontinuation” 18% Cluster 4: “low then high adherence” 11% Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl

@eular_org recommendations session #EULAR2023 - and the first recommendation is one I’m so glad is up front: Adult Onset Still’s Disease (AOSD) and Systemic JIA (sJIA) are the same disease. If anything, it’s the really young sJIA (<18 months old) which is different @RheumNow https://t.co/OCDeeNtNoR

@eular_org recommendation for AOSD/sJIA: An IL-1 or IL-6 inhibitor should be initiated as early as possible when the diagnosis is established #EULAR2023 @RheumNow https://t.co/xNUdpGDxb9

#EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh

One new overarching principle for @eular_org PsA recommendations: “The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile” Wonder what triggered that #EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za

The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO

New 2023 @eular_org SLE recommendations Key changes, in response to evidence: - more caution re: steroids - biologics earlier - combo therapy (BEL or CNI/VCS) considered for lupus nephritis #EULAR2023 @RheumNow https://t.co/J3Lp8owRyT

Key points from #EULAR2023 on how to manage SLE @RheumNow https://t.co/vJy7Cg7w8N

Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009, #EULAR2023 @RheumNow https://t.co/ya41nJG6qK

#ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations ⁦@RheumNow⁩ #EULAR2023 ⁦@eular_org⁩ https://t.co/8mbNt2n64v

#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK